- Trials with a EudraCT protocol (917)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
917 result(s) found for: Colorectal Cancer AND Cancer.
Displaying page 13 of 46.
EudraCT Number: 2015-005464-42 | Sponsor Protocol Number: 2335/2015 | Start Date*: 2016-06-16 | |||||||||||||||||||||
Sponsor Name:Gustave Roussy | |||||||||||||||||||||||
Full Title: A phase II study to assess the efficacy of the anti-PD-L1 antibody atezolizumab (MPDL3280A) administered with stereotactic ablative radiotherapy (SABR) in patients with metastatic tumours | |||||||||||||||||||||||
Medical condition: Patients with one of following metastatic tumours: - Metastatic colorectal cancer - Metastatic non-small lung cancer - Metastatic renal cell carcinoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004214-41 | Sponsor Protocol Number: LSO-OL006 | Start Date*: 2007-04-19 | |||||||||||
Sponsor Name:Light Science Oncology Inc. | |||||||||||||
Full Title: A Multicenter Multinational Phase 3 Randomized Study to Evaluate the Safety and Efficacy of Treating Colorectal Cancer Patients with Recurrent Liver Metastases using the LitxTM System plus Chemothe... | |||||||||||||
Medical condition: Patients with recurrent liver metastases from colorectal cancer who have progressed on either FOLFOX4 or FOLFIRI | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) LV (Completed) IT (Completed) DE (Completed) AT (Completed) SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000627-13 | Sponsor Protocol Number: C201 | Start Date*: 2018-06-06 | ||||||||||||||||||||||||||
Sponsor Name:GAMAMABS Pharma | ||||||||||||||||||||||||||||
Full Title: OPEN, NON CONTROLLED, PARALLEL COHORTS, MULTICENTER, PHASE 2A STUDY FOR THE EVALUATION OF THE ANTITUMOR ACTIVITY OF GM102 SINGLE AGENT AND IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ... | ||||||||||||||||||||||||||||
Medical condition: Patients with locally advanced or metastatic colorectal cancer (CRC), having received at least two lines of therapy for the locally advanced or metastatic CRC disease. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: CZ (Completed) BE (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-002214-17 | Sponsor Protocol Number: NL78220.029.21 | Start Date*: 2023-04-24 | ||||||||||||||||
Sponsor Name:Amsterdam University Medical Centers | ||||||||||||||||||
Full Title: COLLISION RELAPSE trial - Recurrent colorectal liver metastases: repeat local treatment +/- neoadjuvantsystemic therapy - a phase III prospective randomized controlled trial | ||||||||||||||||||
Medical condition: Recurrent colorectal liver metastases | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005547-27 | Sponsor Protocol Number: GO28074 | Start Date*: 2012-10-24 | |||||||||||||||||||||
Sponsor Name:Genentech, Inc. | |||||||||||||||||||||||
Full Title: A PHASE II, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF FOLFIRI + MEHD7945A VERSUS FOLFIRI + CETUXIMAB IN SECOND LINE IN PATIENTS WITH KRAS WILD-TYPE METASTATIC ... | |||||||||||||||||||||||
Medical condition: Colorectal cancer that does not carry mutation in the KRAS gene | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) BE (Completed) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-005296-16 | Sponsor Protocol Number: OLGA | Start Date*: 2013-02-26 | |||||||||||
Sponsor Name:University Medical Center Hamburg-Eppendorf | |||||||||||||
Full Title: Capecitabine and bevacizumab with radiotherapy after 3-6 months chemotherapy for patients with oligometastatic colorectal cancer (OLGA trial) | |||||||||||||
Medical condition: Patients neither being progressive nor resectable after 3-6 months chemotherapy for oligometastatic (up to 3 lesions/5 sites) colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003662-27 | Sponsor Protocol Number: CA209-9X8 | Start Date*: 2018-04-04 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer | |||||||||||||
Medical condition: Metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000834-50 | Sponsor Protocol Number: MGN1703-C06 | Start Date*: 2014-07-09 | |||||||||||
Sponsor Name:MOLOGEN AG | |||||||||||||
Full Title: IMPALA-Trial: Evaluation of an immunomodulatory maintenance treatment in patients with metastatic colorectal cancer with tumor reduction during induction treatment - A phase III trial | |||||||||||||
Medical condition: Metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Completed) BE (Prematurely Ended) IT (Ongoing) EE (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005284-98 | Sponsor Protocol Number: CATROP-2007 | Start Date*: 2009-02-20 | |||||||||||||||||||||
Sponsor Name:Servicio de Anestesiología y Reanimación | |||||||||||||||||||||||
Full Title: Ensayo Clínico aleatorio y a doble cieo de eficacia analgésica postoperatoria en cirugía colo-rectal y cirugía hepática con infusión contínua de anestesico local verus suero salino en la incisión q... | |||||||||||||||||||||||
Medical condition: Dolor postoperatorio en pacientes sometidos a tratamiento quirúrgico de neoplasia colo-rectal o bien a cirugía hepática | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000218-20 | Sponsor Protocol Number: LICC01 | Start Date*: 2011-09-21 | |||||||||||
Sponsor Name:Universitätsmedizin Mainz | |||||||||||||
Full Title: LICC: L-BLP25 in Patients with Colorectal Carcinoma after curative resection of hepatic metastases – a randomized, placebo-controlled, multicenter, multinational, double blinded phase II trial | |||||||||||||
Medical condition: Patients with metastatic colorectal carcinoma (CRC), who have undergone a complete resection of their primary tumor and recent resection of their liver metastases (R0 or R1) with curative intent. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002071-34 | Sponsor Protocol Number: ALLOCATE | Start Date*: 2019-10-31 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Vejle Hospital | ||||||||||||||||||||||||||||||||||||||
Full Title: Allocation of patients with pre-treated solid tumors to anti-cancer therapy based on gene expression drug response prediction - a phase II basket trial | ||||||||||||||||||||||||||||||||||||||
Medical condition: Breast cancer Ovarian cancer Lung cancer Colorectal cancer Prostate cancer Pancreatic cancer | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-002333-29 | Sponsor Protocol Number: GEMCAD-1601 | Start Date*: 2017-04-19 | |||||||||||
Sponsor Name:GEMCAD (Grupo Español Multidisciplinar en Cáncer Digestivo) | |||||||||||||
Full Title: Preoperative induction therapy with 12 weeks of Panitumumab in combination with mFOLFOX-6 in an enriched population (Quadruple Wild-Type) of patients with mrT3 rectal cancer of the middle third wit... | |||||||||||||
Medical condition: Patients with rectal adenocarcinoma of intermediate risk (defined by magnetic resonance imaging [MRI]), without mutations in KRAS, BRAF, NRAS and PI3KCA, who are candidates for preoperative treatment. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000265-20 | Sponsor Protocol Number: LM02 | Start Date*: 2012-06-06 |
Sponsor Name:ABCSG (Austrian Breast & Colorectal Cancer Study Group) | ||
Full Title: A perioperative, single-arm multicenter Phase II academic trial to investigate the efficacy and safety of panitumumab in combination with irinotecan/5-fluorouracil/leucovorin (FOLFIRI) in patients ... | ||
Medical condition: previously untreated, wild-type RAS, potentially resectable colorectal cancer liver metastases | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-000276-41 | Sponsor Protocol Number: SUMO | Start Date*: 2020-03-05 |
Sponsor Name:Erasmus MC | ||
Full Title: Study on the effects of an OCT2/MATE1 substrate (metformin) and inhibitor (cimetidine) on the exposure of trifluridine/tipiracil (Lonsurf®) in patients with metastatic colorectal cancer (mCRC). | ||
Medical condition: patients with mCRC with an indication for lonsurf treatment. | ||
Disease: | ||
Population Age: | Gender: | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003008-15 | Sponsor Protocol Number: CAPRI2 | Start Date*: 2021-05-27 | |||||||||||
Sponsor Name:GRUPPO ONCOLOGICO DELL'ITALIA MERIDIONALE | |||||||||||||
Full Title: CAPRI 2 GOIM study: investigate the efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wt tumors at start of first line. | |||||||||||||
Medical condition: mCRC patients with RAS/BRAF wild type tumors at start of first line treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003770-85 | Sponsor Protocol Number: DKFZ-2019-007 | Start Date*: 2020-08-20 |
Sponsor Name:German Cancer Research Center (DKFZ) | ||
Full Title: Effect of low-dose acetylsalicylic acid on early detection of advanced colorectal neoplasms | ||
Medical condition: Screening for advanced colorectal neoplasms. Male individuals aged 40 to 79 years scheduled for screening colonscopy and no use of acetylsalicylic acid (or other drugs with an effect on the blood ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002533-14 | Sponsor Protocol Number: REVERT | Start Date*: 2021-02-15 | ||||||||||||||||
Sponsor Name:DIP. MEDICINA DEI SISTEMI UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA | ||||||||||||||||||
Full Title: REVERT – taRgeted thErapy for adVanced colorEctal canceR paTients. | ||||||||||||||||||
Medical condition: unresectable metastatic colorectal cancer (mCRC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004415-39 | Sponsor Protocol Number: TO-TAS0728-101 | Start Date*: 2019-02-05 | |||||||||||||||||||||||||||||||
Sponsor Name:Taiho Oncology, Inc. | |||||||||||||||||||||||||||||||||
Full Title: A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF TAS0728, AN ORAL COVALENT BINDING INHIBITOR OF HER2, IN SUBJECTS WITH ADVANCED SOLID TUMORS W... | |||||||||||||||||||||||||||||||||
Medical condition: Urothelial cancer with HER2 or HER3 mutation Biliary tract cancer with HER2 or HER3 mutation Breast cancer with HER2 or HER3 mutation Breast cancer with HER2 amplification/overexpression as per AS... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) ES (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-002105-44 | Sponsor Protocol Number: ML20982 | Start Date*: 2008-07-02 | ||||||||||||||||
Sponsor Name:Military Medical Academy Hospital for Active Treatment, Sofia | ||||||||||||||||||
Full Title: Open – label, non randomized clinical study of Neoadjuvant chemotherapy with FOLFIRI and Avastin in patients with non-resectable liver metastases of colorectal cancer | ||||||||||||||||||
Medical condition: Metastatic (liver metastases) colorectal cancer, with no prior chemotherapy. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003440-66 | Sponsor Protocol Number: D8480C00013 | Start Date*: 2006-09-11 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizuma... | |||||||||||||
Medical condition: This is a Phase II / III trial in Patients with Previously Untreated Metastatic Colorectal Cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) AT (Completed) CZ (Completed) DE (Completed) SK (Completed) HU (Completed) IT (Completed) GB (Completed) FI (Completed) LV (Completed) MT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
